Alzheimer’s/Dementia

Side Effects of the New Alzheimer’s Drugs

On July 2, the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab-azbt), an intravenous drug designed to slow the progression of Alzheimer’s disease.1 About three weeks…

Jul 11, 2024